Comparative Pharmacology
Head-to-head clinical analysis: FUZEON versus SYMMETREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUZEON versus SYMMETREL.
FUZEON vs SYMMETREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fusion inhibitor; binds to gp41 of HIV-1, preventing conformational changes required for fusion with host CD4+ T-cell membrane.
Inhibits influenza A virus uncoating and viral RNA replication; increases dopamine release and blocks dopamine reuptake in the CNS.
90 mg subcutaneously twice daily
100 mg orally twice daily; may increase to 200 mg orally twice daily if tolerated, usually in divided doses. For Parkinson's disease, 100 mg orally twice daily; for drug-induced extrapyramidal reactions, 100 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 3.8 hours; clinically, steady-state plasma concentrations are achieved within 2-3 days with subcutaneous administration
Terminal half-life: 24-48 hours (young adults); 48-72 hours (elderly); may extend to 7-10 days in severe renal impairment. Clinically, steady-state achieved in 4-7 days.
Renal: approximately 70% as unchanged drug via glomerular filtration; fecal: <5% as metabolites
Primarily renal excretion (90-95% unchanged) via glomerular filtration and tubular secretion; minor fecal (<5%). Dose adjustment required in renal impairment.
Category C
Category C
Antiviral
Antiviral and Antiparkinsonian